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Abstract
Meige syndrome is a type of segmental dystonia that manifests a combination of blepharospasm and
oromandibular dystonia and is often associated with other types of craniocervical dystonia. Although the precise
pathogenesis of primary Meige syndrome remains to be elucidated, it has been suggested that this movement
disorder might be a basal ganglia disorder. Multiple single case reports and open-labeled small case series have
shown that globus pallidus internus deep brain stimulation (GPi-DBS) could result in therapeutic benefits in patients
with severe Meige syndrome. However, randomized and controlled trials are necessary to accurately assess the
safety and therapeutic efficacy of GPi-DBS in treating patients with Meige syndrome. This short commentary
introduces the current use of GPi-DBS in the treatment of medically refractory Meige syndrome.
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Introduction
Meige syndrome was first described in detail by Henri Meige [1],
the French neurologist. This movement disorder is a type of dystonia,
and is also known as Bruegel’s syndrome [2] and oral facial dystonia.
Meige syndrome is characterized by the presence of blepharospasm in
combination with oromandibular dystonia and is often associated with
other types of craniofacial dystonias [3]. Meige syndrome affects
women more often than men (2:1 ratio) and its symptom onset is
typically between 30 and 70 years of age. In general, Meige syndrome
responds poorly to oral pharmacotherapy [4-6]. A double-blind study
[7] has proven that trihexyphenidyl, an antimuscarinic agent, is
effective in the treatment of segmental craniocervical dystonias that
include Meige syndrome. However, only 1 of 9 patients with Meige
syndrome responded to trihexyphenidyl in this study. The United
States Food and Drug Administration (FDA) has approved botulinum
toxin type A (BTA) as a first-line treatment for blepharospasm and
cervical dystonias [3,8]. Since blepharospasm associated with Meige
syndrome is usually more severe than isolated blepharospasm, it is
difficult to obtain satisfactory results with BTA injections in the
treatment of Meige syndrome [8-10]. In addition, BTA treatments have
the potential to cause adverse events such as diminished responses,
facial weakness, dysphagia, dry mouth, flu-like syndrome, and the
development of antibodies against botulinum toxin [8,11-13]. Despite
these best medical attempts, intractable disabling dystonias often
persist in some patients with primary Meige syndrome.
The precise cause of primary Meige syndrome is poorly understood,
however it is thought to be a variant of idiopathic torsion dystonia
[14,15]. As in other dystonia syndromes, multiple single case reports
and open-labeled small case series have shown that bilateral deep brain
stimulation (DBS) of the globus pallidus internus (GPi), which is the
major basal ganglia output nucleus, can produce powerful therapeutic
benefits in medically intractable primary Meige syndrome [16]. The
therapeutic efficacy of GPi-DBS as determined by Burke-Fahn-
Marsden dystonia rating scale total movement score (BFMDRS-M)
showed an improvement of 64.3% (SD 29.5) [17]. In the selected Meige
syndrome patients with longer follow-up periods, that is, for more than
5 years (mean ± SD, 80.7 ± 21.9 months), the therapeutic efficacy of
GPi-DBS resulted in an improvement of 70.9 ± 17.1% (mean ± SD), as
determined by BFMDRS-M [18-21]. Overall clinical outcomes suggest
that GPi-DBS might be more efficient in patients with Meige syndrome
than in those with other types of focal and segmental dystonias [17].
The beneficial effects of GPi-DBS in patients with Meige syndrome
could be maintained for more than 5 years after surgery. However, the
true benefits of GPi-DBS are currently unclear due to the lack of
randomized controlled trials in patients with Meige syndrome. The
stereotactic coordinates for active contacts of the DBS lead usually are
usually located in the posteroventrolateral portion of the GPi [22-26].
Stimulation parameters used in patients with primary Meige syndrome
were highly variable with amplitude of 1.0–5.2 volts, frequency of 60–
235 Hz, and pulse width of 90–500 μs [16,18-29]. In our experience, a
long pulse width (e.g. 450 μs) usually yielded good clinical results
[21,27,28]. Using the meta-regression analysis on patients with
dystonias that include Meige syndrome, Andrews et al. reported that
the only variable showing a trend towards association with improved
percentage outcome by GPi-DBS was a shorter time duration between
the disease onset and DBS initiation (p=0.06) [17].
GPi-DBS should be considered only if the patients experienced
markedly disabling motor symptoms associated with Meige syndrome
even though they had received other treatments options, administered
by skilled and experienced neurologists [3]. The exclusion criteria for
the use of GPi-DBS in patients with Meige syndrome are essentially the
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same as those applied to patients with other primary dystonias. They
include the presence of brain atrophy and/or other organic lesions,
marked cognitive impairment, acute psychiatric changes, severe
depression, and other coexisting medical disorders that would increase
surgical risk [30]. Perioral tightness [18] and stimulation-induced
severe parkinsonism [29] have been reported as un-adjustable
complications caused by GPi-DBS in patients with Meige syndrome.
Ostrem et al. reported difficulty with coordination and slowness in
motor function including worsening of handwriting, typing, balance,
and walking in 4 of 6 patients with Meige syndrome [22]. We also
should pay a careful attention to depression, which can be a potential
risk factor for suicide after GPi-DBS [31]. The parallel organization of
functionally segregated cortico-basal ganglia-thalamo-cortical
feedback loops invokes the possibility that GPi-DBS could influence
motor as well as the other functional loops including associative or
limbic loops [32,33]. Ventral two-thirds of the posterior GPi is the
primary motor cortex-related territory and dorsal one-third of the
posterior GPi is the prefrontal cortex-related territory [34,35]. More
dorsal and anterior to the motor cortex-related territory is the
supplementary motor area-related territory, while the most medial part
of the GPi corresponds to the limbic cortex-related territory [34,35].
For those reason, correct positioning of the active electrodes and
careful follow-up assessments of non-motor symptoms including
psychiatric conditions after GPi-DBS should be required. In summary,
bilateral GPi-DBS could produce a significant improvement of
medically refractory dystonia symptoms in patients with Meige
syndrome. In the near future, well-designed studies with randomized
and controlled trials will be required to establish GPi-DBS as an
effective and tolerable treatment option for Meige syndrome.
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